

**Supplementary Table 3. Changes in eGFR after drug initiation in patients in the sacubitril-valsartan and valsartan groups in cohort 1**

Follow-up visit (mo)	eGFR (mL/min/1.73 m <sup>2</sup> )				Difference (%) <sup>a</sup>		Drug dose (mg)	
	Total	Sacubitril-valsartan	Valsartan	p-value	Sacubitril-valsartan	Valsartan	Sacubitril-valsartan	Valsartan
Baseline	76.5 ± 28.7	76.1 ± 33.1	76.8 ± 24.6	0.79			93.6 ± 60.4	96.3 ± 37.0
1	64.4 ± 28.5	63.6 ± 32.4	65.0 ± 24.9	0.58	16.4	15.4	122.0 ± 99.0	103.6 ± 45.7
3	64.7 ± 29.1	64.1 ± 33.2	65.3 ± 24.9	0.70	15.8	15.0	128.3 ± 106.6	101.4 ± 41.7
6	63.6 ± 29.1	62.6 ± 31.5	64.5 ± 26.7	0.49	17.7	16.0	134.4 ± 112.4	103.9 ± 44.0
12	63.5 ± 30.3	62.9 ± 34.2	64.0 ± 26.5	0.74	17.3	16.7	145.0 ± 121.8	104.2 ± 42.9

Data are expressed as mean ± standard deviation.

eGFR, estimated glomerular filtration rate.

<sup>a</sup>The difference in values is expressed as a percentage, and the positive value indicates a decrease in kidney function compared to the baseline.